The short version of Cardarine fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-23. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
=== MSIR model === For many infections, including measles, babies are not born into the susceptible compartment but are immune to the disease for the first few months of life due to protection from maternal antibodies (passed across the placenta and additionally through colostrum). This is called passive immunity. This added detail can be shown by including an M class (for maternally derived immunity) at the beginning of the model.
==== A, Short Order ==== The Unitized Group Ration – A, Short Order (UGR-A SO) consists of meals intended to supplement the UGR-A and expand available food options or feed larger groups, especially where alternate dining facilities or existing meal options are unavailable. Most UGR-A SO meals are based on fast food, pub food, and finger food. The UGR-A SO has the same kilocalorie amount, storage, and minimum shelf life as the regular UGR-A.
=== Fission chain reaction realized === During this period the Hungarian physicist Leó Szilárd realized that the neutron-driven fission of heavy atoms could be used to create a nuclear chain reaction. Such a reaction using neutrons was an idea he had first formulated in 1933, upon reading Rutherford's disparaging remarks about generating power from neutron collisions. However, Szilárd had not been able to achieve a neutron-driven chain reaction using beryllium. Szilard stated, "...if we could find an element which is split by neutrons and which would emit two neutrons when it absorbs one neutron, such an element, if assembled in sufficiently large mass, could sustain a nuclear chain reaction." On 25 January 1939, after learning of Hahn's discovery from Eugene Wigner, Szilard noted, "...if enough neutrons are emitted...then it should be, of course, possible to sustain a chain reaction. All of the things which H. G. Wells predicted appeared suddenly real to me." After the Hahn-Strassman paper was published, Szilard noted in a letter to Lewis Strauss, that during the fission of uranium, "the energy released in this new reaction must be very much higher than all previously known cases...," which might lead to "large-scale production of energy and radioactive elements, unfortunately also perhaps to atomic bombs." Szilard now urged Fermi (in New York) and Frédéric Joliot-Curie (in Paris) to refrain from publishing on the possibility of a chain reaction, lest the Nazi government become aware of the possibilities on the eve of what would later be known as World War II.
Sources: en.wikipedia.org
=== Gas treatment === Aqueous monoethanolamine (MEA), diglycolamine (DGA), diethanolamine (DEA), diisopropanolamine (DIPA) and methyldiethanolamine (MDEA) are widely used industrially for removing carbon dioxide (CO2) and hydrogen sulfide (H2S) from natural gas and refinery process streams. They may also be used to remove CO2 from combustion gases and flue gases and may have potential for abatement of greenhouse gases. Related processes are known as sweetening.
In the conflict's early months it appeared that Gaddafi's government—with its greater fire-power—would be victorious. Both sides disregarded the laws of war, committing human rights abuses, including arbitrary arrests, torture, extrajudicial executions, and revenge attacks. On 26 February, the United Nations Security Council passed Resolution 1970, suspending Libya from the UN Human Rights Council, implementing sanctions and calling for an International Criminal Court (ICC) investigation into the killing of unarmed civilians. In March, the Security Council declared a no-fly zone to protect the civilian population from aerial bombardment, calling on foreign nations to enforce it; it also specifically prohibited foreign occupation. Ignoring this, Qatar sent hundreds of troops to support the dissidents and, along with France and the United Arab Emirates, provided weaponry and military training to the NTC. NATO announced that it would enforce the no-fly zone. On 30 April a NATO airstrike killed Gaddafi's sixth son and three of his grandsons in Tripoli. This Western military intervention was criticized by various leftist governments, including those that had criticized Gaddafi's response to the protests, because they regarded it as an imperialist attempt to secure control of Libya's resources. In June, the ICC issued arrest warrants for Gaddafi, his son Saif al-Islam, and his brother-in-law Abdullah Senussi, head of state security, for charges concerning crimes against humanity.
Similarly, modifications to the tRNA-linked bases that differ from the host system may reduce the translation of proteins quantitatively and qualitatively. For example, translating a foreign gene in another host system that did not contain the required tRNA resulted in early termination at the codon where the tRNA was missing. Collectively, with heterologous expression, when the host translation systems are different from the native system that the genes are being introduced from, coding errors, frameshifts, or premature or improper sequence termination are frequent. Consequently, this leads to a lower yield of functional proteins or unintended overexpression of the protein. These errors are especially prominent with the significant and unnatural increase in demand for host system biological machinery. Often, this causes the reallocation of cellular resources from normal processes to the production of the heterologous protein. Specifically, this strains tRNA and amino acid supply, quality control systems and secretion systems, as well as NADPH required for anabolic processes. Moreover, unnatural heterologous protein buildup also leads to adverse host effects. Overall the implications are not only evident in low product yields but also host stress responses and decreased host viability. There are many areas of active research addressing these limitations of utilizing heterologous expression, especially in a commercial setting.
Sources: en.wikipedia.org
== Experimental design == The apparatus consists of a gas chromatograph equipped with an odour port (ODP), in place of or in addition to conventional detectors, from with human assessors sniff the eluates. The odour port is characterised by its nose-cone design connected to the GC instrument by a transfer line. The odour port is commonly glass or polytetrafluoroethylene. It is generally placed 30–60 cm away from the instrument, extending from the side such that it is not affected by the hot GC oven. The deactivated silica transfer line is generally heated to prevent the condensation of less-volatile compounds. It is flexible so that the assessor can adjust it according to their comfortable sitting position. As traditional warm and dry carrier gases may dehydrate the mucous membrane of the nose, volatiles are delivered via auxiliary gas or humidified carrier gas, with relative humidity (RH) of 50–75%, to ease the dehydration. The olfactometric detector may be coupled with, or connected in parallel to, a flame ionization detector (FID) or mass spectrometer (MS). Moreover, multiple odour ports may be set-up. In these cases, the eluate is generally split evenly between the detectors to allow it to reach the detectors simultaneously.
DNA sequence data shows that the mummies had Haplogroup R1a (Y-DNA) characteristic of western Eurasia in the area of East-Central Europe, Central Asia and the Indus Valley. This has created a stir in the Turkic-speaking Uighur population of the region, who claim the area has always belonged to their culture, while it was not until the 10th century that Uighurs are said by scholars to have moved to the region from Central Asia. American Sinologist Victor H. Mair claims that "the earliest mummies in the Tarim Basin were exclusively Caucasoid, or Europoid" with "east Asian migrants arriving in the eastern portions of the Tarim Basin around 3,000 years ago", while Mair also notes that it was not until 842 that the Uighur peoples settled in the area. Other mummified remains have been recovered from around the Tarim Basin at sites including Qäwrighul, Yanghai, Shengjindian, Shanpula (Sampul), Zaghunluq, and Qizilchoqa.
one who is a carrier for the disease, having only one normal allele for the insulin receptor) will not be affected. Two heterozygous parents have, in theory, a one in four chance of having a child with the disease, and two thirds of their unaffected children will be carriers. However, because spontaneous abortion (miscarriage) often results when the fetus has the disease, in actuality the proportion of children born alive with Donohue syndrome will be lower than 25%. It is possible to do a genetic test to identify carriers, but because it is so rare, this is not usually done unless there is reason to suspect that the individual being tested is a carrier, for instance having an affected sibling or cousin. As expected for a genetic disease that can be caused by many different mutations, it is not limited to a specific ethnic group, and has been seen in people of various ethnicities.
=== Copper toxicity from excess exposures === In humans, the liver is the primary organ of copper-induced toxicity. Other target organs include bone and the central nervous and immune systems. Excess copper intake also induces toxicity indirectly by interacting with other nutrients. For example, excess copper intake produces anemia by interfering with iron transport and/or metabolism. The identification of genetic disorders of copper metabolism leading to severe copper toxicity (i.e., Wilson disease) has spurred research into the molecular genetics and biology of copper homeostasis (for further information, refer to the following section on copper genetic diseases). Much attention has focused on the potential consequences of copper toxicity in normal and potentially susceptible populations. Potentially susceptible subpopulations include hemodialysis patients and individuals with chronic liver disease. Recently, concern was expressed about the potential sensitivity to liver disease of individuals who are heterozygote carriers of Wilson disease genetic defects (i.e., those having one normal and one mutated Wilson copper ATPase gene) but who do not have the disease (which requires defects in both relevant genes). However, to date, no data are available that either support or refute this hypothesis.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.